Context: Mutations in the kisspeptin receptor (KISS1R) gene have been reported in a few patients with normosmic congenital hypogonadotropic hypogonadism (nCHH) (OMIM #146110).
I
n congenital hypogonadotropic hypogonadism (CHH), gonadotropin deficiency results in partial or complete pubertal failure and/or infertility (1) . The other pituitary hormones are normal in CHH. CHH exists as three main variants: Kallmann syndrome characterized by an association with anosmia due to an agenesis of olfactory bulbs, normosmic CHH (nCHH), and syndromic CHH (1) . The neuropeptide GnRH is released by hypothalamic neurons into the hypothalamic-pituitary portal system and plays a key role in regulating puberty and reproduction. GnRH acts on the anterior pituitary to activate the production and release of LH and FSH (2) . Several gene variants responsible for GnRH failure have been identified in patients with CHH (1) .
The kisspeptin receptor (KISS1R) is a G-proteincoupled receptor expressed in GnRH neurons and encoded by KISS1R. The role for KISS1R in controlling the gonadotropic axis was initially recognized in 2003 when loss-of-function KISS1R mutations were linked to nCHH (3, 4) . Relatively few inactivating KISS1R variants have been reported to date in patients with nCHH (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) . The endocrine phenotype due to KISS1R loss of function varies from partial to complete gonadotropic deficiency in both sexes. No genotype-phenotype correlation has been reported to date for KISS1R loss of function mutations.
A multitude of studies have demonstrated a crucial role for kisspeptin in gonadotropic axis activity at different ages in all studied species except birds (17) . In humans, kisspeptin is necessary for primary sexual characteristics to be fully developed in men (10, 11) and makes a major contribution to gonadotropic axis reactivation at puberty (3, 4, 18) . In adulthood, kisspeptin administration stimulates LH and FSH secretion through a GnRH-dependent pathway in both men and women; this effect is strongest during the periovulatory phase (19) . Kisspeptin-induced LH release correlates with estradiol levels in women (20, 21) . Kisspeptin enhances ovarian follicle maturation during in vitro fertilization (19) and participates in sexual and emotional brain processing, probably via direct effects on limbic structures (22) . In addition, Kisspeptin and its receptor are expressed in the human ovary and endometrium (23) . Furthermore, a recently reported correlation linking the outcome of intracytoplasmic sperm injection to plasma kisspeptin levels and endometrial thickness suggests a role for kisspeptin in implantation (24) .
The exact function of kisspeptin in inducing the preovulatory LH surge remains uncertain and may diverge across species. In rodents, kisspeptin signaling is mandatory for induction of the estradiol-induced LH surge (2, 25) , whereas kisspeptin stimulates LH release but not ovulation in mares (26) . By analogy with rodent models, kisspeptin is suspected to be involved in estradiol-induced positive feedback on the LH surge in humans. GnRH pulsatile therapy to induce ovulation in patients with CHH is relatively well standardized (1) . Because KISS1R inactivation is believed to induce GnRH deficiency, GnRH pulsatile treatment has been used to treat KISS1R-mutated male (6, 9) and in female patients (12) .
Here, we report a homozygous loss-of-function KISS1R mutation in a female patient with normosmic CHH. We found complete inactivation of the mutated KISS1R signaling pathway due to deficient cell surface expression of the receptor. Nevertheless, pulsatile GnRH treatment induced an LH surge and an ovulation, which led us to question the exact role of kisspeptin in the occurrence of the LH surge in women.
Patient and Methods

Patient
A 28-year-old Senegalese woman was referred for evaluation of primary amenorrhea. She was the second child of consanguineous parents. She took hormonal contraception from 21 to 27 years of age. She had no breast development prior to starting oral contraceptives. Neither her mother nor her two brothers had a history of delayed puberty or impaired fertility; no information was available on the father. She had a height of 182 cm and weight of 55 kg with no dysmorphism. She always had a low body mass index without eating disorders or intensive sports activity. Breast development was Tanner stage 2, which could be explained by the use of a combined hormonal treatment with low ethinyl-estradiol (0.03 mg per pill), which has been started late. Her axillae and pubis had been depilated. Olfactometry tests were performed as described elsewhere (27) and were normal. Hormone assays revealed a low estradiol level (11.8 pg/mL) and inappropriately normal gonadotropin levels (LH, 4.5 IU/L; FSH, 6.6 IU/L), a normal prolactin level, a low level of anti-Mullerian hormone (AMH; 1.18 ng/mL), and an undetectable level of inhibin B (,10 pg/mL). The GnRH agonist test was done with an intravenous injection of 100 mg of GnRH and elicited a high-normal LH response and mild FSH overreaction [LH, 4.5 (T0) to 35.9 IU/L (T60); FSH, 6.6 (T0) to 19.6 (T60) IU/L]. Her thyroid function was normal. Cerebral magnetic resonance imaging was normal, including the presence of normal olfactory bulbs. Pelvic sonography showed a small uterus (45 3 13 3 20 mm) and small ovaries with few follicles. The right ovary measured 20 by 11 mm with follicles, and the left ovary was atrophic without follicles. Her karyotype was 46 XX.
Treatment
GnRH treatment to induced ovulation
The proband was treated by GnRH pulses to induce ovulation. These pulses were delivered subcutaneously by an infusion pump system (LutrePulse; Ferring SA, Gentilly, France). The gonadorelin acetate (Lutrelef; Ferring SA, Gentilly, France) was delivered automatically every 90 minutes at a dose of 20 mg. Eight cycles of treatments were performed. We maintained the pulse frequency during all cycles and throughout the treatment.
Treatment by estradiol and progesterone for endometrial evaluation
We administered estradiol at increasing doses and sequentially combined it with progesterone to carry out a monitoring of endometrium. We started with 2 mg estradiol orally for 1 week and gradually increased to 3 and then 4 mg. Given the weak endometrial response, we used a percutaneous route (patch) at 200 mg twice a week instead of the oral route without a better response. We therefore took an oral route facilitating the proband's compliance and added progesterone.
Genotyping
Genomic DNA was extracted from blood lymphocytes and used for PCR amplification of the exon and exon-intron boundaries of KISS1, KISS1R, TAC3 TACR3, GNRH1, and GNRHR. PCR products were sequenced directly using the 3100 sequencer (Applied Biosystems, Courtaboeuf, France) (3). The proband, the mother, and brothers gave informed consent for genetic analysis. To exclude rare polymorphisms, we checked the dbSNP database and the 1000 Genomes Project database. The sequence was aligned to the reference sequence NM_032551 (KISS1R).
Expression plasmid
The wild-type (WT) KISS1R sequence was cloned in a pcDNA3.1 expression vector. To study cell surface expression of KISS1R, a human influenza hemagglutinin (HA) epitope (YPYDVPDYA) was added at the N-terminal end of KISS1R after the initial methionine to obtain WT-HA-KISS1R plasmids (15) . The fragment including the mutation was amplified by PCR with the patient's DNA and the following primers: forward, CAGTCCTGCAGGGGCAGGTGCTGGCAGAG; reverse, CCACTGCTCCCTGGCTTCTGCG. The PCR fragment was cut by the restriction enzymes SbfI (New England Biolabs, Evry, France) and KflI (Thermo Fisher Scientific, Courtaboeuf, France) and subcloned into WT-HA-KISS1R in place of the WT sequence to obtain the L318P-HA-KISS1R plasmid.
Cell culture HEK293 cells were cultured in DMEM (61965, high glucose, GlutaMAX; Thermo Fisher Scientific) supplemented with 10% fetal calf serum, 100 U/mL penicillin, and 100 mg/mL streptomycin (Invitrogen, Carlsbad, CA) and 25 mM HEPES (Invitrogen). The cells were incubated in a humidified 95% air and 5% CO 2 controlled atmosphere at 37°C. The medium was changed every 2 or 3 days. Passages were performed twice a week.
Functional analyses
Transfection with WT-HA-KISS1R or L318P-HA-KISS1R plasmids was performed using Fugene HD (Roche, Basel, Switzerland) according to the manufacturer's instructions 24 hours after seeding at a density of 2 3 10 6 HEK293 cells in 10-cm dishes. After 24 hours, the cells were distributed in 384-well plates at a density of 2 3 10 4 cells per well. At 48 hours after transfection, total inositol phosphate (IP) level was measured using the HTRF IP-One assay (Cisbio Bioassays, Codolet, France) according to the manufacturer's instructions. Briefly, the transfected cells were stimulated with kisspeptin-10 (Kp-10) for 1 hour at 37°C. Then, the fluorophore d2-labeled IP1 and anti-IP1 antibody conjugated to cryptate (IP-One Tb) were added for 1 hour at room temperature. The plate was read at 620 and 665 nm using the PARADIGM Detection Platform (Beckman Coulter, Brea, CA). Each functional analysis was performed in triplicate. We used GraphPad Prism software (GraphPad, San Diego, CA) to draw the response curve and to calculate IP values. IP values were expressed as percentages of maximal WT-HA-KISS1R stimulation, which was taken as 100%.
Cell immunofluorescence
Transfection with WT-HA-KISS1R or L318P-HA-KISS1R was performed using Fugene HD (Roche) 24 hours after seeding at a density of 1.0 3 10 5 cells/mL of medium in 12-well culture plates containing coverslips coated with poly-L-lysine (SigmaAldrich, Saint Louis, MO). The cells were fixed with 4% formaldehyde 48 hours after transfection. Cells were left either unpermeabilized or permeabilized with 0.25% Triton X-100/ PBS. We used primary rat anti-HA-probe antibody and a secondary donkey anti-rat IgG H+L (Alexa Fluor ® 488) antibody (Invitrogen). Images were acquired using a TCS SP8 confocal laser microscope (Leica, Wetzlar, Germany).
Hormone assays
Serum hormone levels were determined by immunoassay. The FSH immunoassay (TRFIA AutoDelfia Wallac; PerkinElmer, Courtaboeuf, France) had a detection limit of 0.033 IU/L, intraassay coefficient of variation (CV) of 2.1% to 4.8%, and interassay CV ,5%. The LH immunoassay (TRFIA AutoDelfia; Wallac) had a detection limit of 0.024 IU/L, intra-assay CV of 1.3% to 3.8%, and interassay CV ,5%. Estradiol was measured by radioimmunoassay (CisBio, Gif-sur-Yvette, France). The detection limit was 0.9 pg/mL (3.3 pmol/L), and the standard curve extended up to 2000 pg/mL (7340 pmol/L). The intraassay and interassay precisions (CV%) determined at four concentrations (63 to 910 pmol/L) were ,11%. The AMH ELISA (AnshLabs, Webster, TX) had a detection limit of 0.2 pmol/L, intra-assay CV ,4% above 5 pmol/L, and interassay CV ,9% at concentrations of 7 to 110 pmol/L. The inhibin B ELISA (AnshLabs), which exhibited no cross-reactivity with activins or inhibin A, had a detection limit of 2.2 pg/mL; intraassay CVs of 4.6% and 2.8% at mean concentrations of 53 and 96 pg/mL, respectively; and interassay CVs of 9.7% and 4.8% at concentrations of 40 and 93 pg/mL, respectively.
Immunohistochemistry
Endometrium was collected for immunohistochemistry analysis by pipelle biopsy. Tissue was then fixed with paraformaldehyde and embedded in paraffin. Historical biopsies from normal endometrium in follicular or luteal phases were used as a comparison. Endometrial sections were dewaxed and were incubated for 30 minutes at 95°C in Target Retrieval Solution (pH 9) (Agilent, Les Ulis, France) and cooled at room temperature. Endogenous peroxidase activity was inactivated in 3% H 2 O 2 . The sections were then washed in Tris-buffered saline (TBS) and blocked for 30 minutes in TBS supplemented with 3% BSA and 0.3% Triton-X100 (Sigma-Aldrich) before incubation with the primary antibody against KISS1R (gp74, 1/1000) overnight at 4°C (28) . After three washes in TBS-Triton 0.2% Tween 20 0.2%, biotin-conjugated antirabbit antibody (Ultratech HRP detection system kit; Immunotech, Marseille, France) was added. The sections were then washed intensively with PBS and incubated with peroxidase-conjugated streptavidin for 1 hour at room temperature. 3.3-Diaminobenzidine tetrahydrochloride (Agilent) was used as a substrate for peroxidase activity. Negative controls were tissue sections incubated without primary antibody and with concentration-matched secondary antibody. The sections were counterstained with Mayer hemalun (MerckMillipore, Fontenay-sous-Bois, France), mounted in Pertex medium (Histolab Products, Gothenburg, Sweden), and examined under a DMR microscope (Leica, Heidelberg, Germany). Images were acquired with a DFW-SX900 camera (Sony, Tokyo, Japan) and Inspector software (Matrox Imaging, Quebec, Canada).
Results
Genotyping
We identified a homozygous c.953T.C transition in exon 5 of KISS1R, leading to substitution of leucine 318 for proline in the seventh transmembrane domain of the kisspeptin protein (p.Leu318Pro). Sequence analysis of other candidate genes, including GNRHR, GNRH1, TAC3, TACR3, and KISS1, identified no pathogenic variants. Sequencing in the mother and two brothers showed a heterozygous c.953T.C transition in the mother and one brother, who had cryptorchidism but did not report delayed puberty; the other brother did not carry the variant (Fig. 1a) . This variant was not present in the dbSNP, Exact, or 1000 Genomes Project databases. Leucine 318 has been strongly conserved during the evolution with very few exceptions. An isoleucine replaces leucine 318 in zebrafish and Xenopus. In none of the organisms was a proline found in place of leucine 318. The in silico analysis has predicted that the Leu318Pro substitution was damaging. This variant was therefore considered as likely pathogenic.
Functional analyses
The potential effect of the Leu318Pro substitution on KISS1R function was investigated by transiently transfecting HEK293 cells with the L318P-HA-KISS1R-encoding plasmid and measuring Kp-10-induced generation of intracellular IP. The HA-tag added at the N-terminal end of KISS1R was shown not to change Kp10-induced IP generation (15) . Kp-10 increased intracellular IP in cells transiently expressing WT-HA-KISS1R but not in nontransfected cells (Fig. 1b) . In cells expressing L318P-HA-KISS1R, Kp-10 did not increase the level of intracellular IP (Fig. 1b) , suggesting deficient expression of the Leu318Pro mutated receptor at the cell surface or a complete absence of coupling with Gq/11.
To differentiate between these two hypotheses, we evaluated cell surface expression of the mutated receptor by incubating HEK293 cells transfected with the WT or mutated expression vector with an antibody against the HA-tag added at the N-terminal end of KISS1R with and without prior cell permeabilization. In nonpermeabilized cells, marked immunostaining was visible at the surface of the WT-HA-KISS1R-transfected cells, whereas no immunostaining was observed on L318P-HA-KISS1R-transfected cells (Fig. 1c) . In contrast, strong intracellular staining was visible in WT-HA-KISS1R-transfected and L318P-HA-KISS1R-transfected cells (Fig. 1c) . These results led us to conclude that the p.Leu318Pro substitution is pathogenic.
Response to GnRH pulsatile treatment
The couple was infertile for 1 year. Indeed, the proband had stopped her contraceptive pill 1 year before consulting. She was in amenorrhea during this period. She never had spontaneous menses. The proband was treated by GnRH pulses (subcutaneous, 20 mg/pulse every 90 minutes) to induce ovulation. The quality of the ovarian response was heterogeneous. Four cycles led to an ovulation obtained between day 19 and day 27 associated with physiologic levels of estradiol (between 250 and 400 pg/mL), whereas three other cycles were unsuccessful. Poor patient adherence to the treatment may have contributed to the failures. In cycles with ovulation, endometrial maturation was limited (thickness ,3 mm) despite an estradiol increase. The failure to achieve a pregnancy and the patient's thin endometrium prompted us to carry out a monitoring of endometrium (Fig. 2) . The endometrial response was poor to estradiol in escalating dosages administered alone then with progesterone. A further cycle of pulsatile GnRH therapy was then performed. Despite the lack of robust evidence to support this practice, we also gave aspirin, vitamin E, and pentoxifylline, with the goal of optimizing endometrial trophicity (29) . We monitored the LH levels in response to GnRH when endometrial thickness reached 5.4 mm. On day 22 after GnRH pump therapy initiation, basal LH levels were slightly elevated (9 IU/L), with low-amplitude peaks after each GnRH pulse (Fig. 3) . On the morning of day 23, the LH level was markedly increased (mean over 120 minutes, 29.00 6 4.31 IU/L; range, 22.90 to 35.30 IU/L) with persistent GnRH-induced LH peaks (Fig. 3) . Ovulation occurred on day 23, and a pregnancy was obtained. Preeclampsia required delivery by caesarean section at a gestational age of 32 weeks. The baby was a boy with normal genitalia. After delivery, the patient remained amenorrheic and was again treated with estrogen and progestin.
KISS1R is expressed in the endometrium
The ability of assisted reproductive technology to produce implantation depends not only on the quality of https://academic.oup.com/jcemthe embryos but also on the development of a mature endometrium under the effect of endocrine and immune factors. Endometrial thickness at the time of ovulation reflects receptivity. A thin endometrium (,6 mm) is associated with lower implantation and pregnancy rates (30) . Given the poor endometrial response in our patient, we evaluated KISS1R expression in her endometrium vs control endometrial samples. In control samples, we observed dense immunoreactive intracellular puncta at the apical pole of epithelial cells, whereas the staining at the basal pole was less intense (Fig. 4a and 4b) . Staining was observed in few stromal cells. Similar intracellular staining was observed in epithelial cells of the patient's endometrium (Fig. 4c) . No staining was observed when the first antibody was omitted (Fig. 4d) . As previously shown, gp74 stains intracellular puncta (28); it was therefore not possible to analyze whether the mutated KISS1R was able to reach the cell surface in endometrial cells.
Discussion
The prevalence of CHH has been estimated at about 1/10,000, and only 30% to 50% of all patients with the nCHH variant have known genetic defects (1). Mutations in GNRHR, TAC3, TACR3, KISS1, and KISS1R account for two-thirds of cases of familial autosomal recessive nCHH. In CHH, GNRHR and TACR3 are the first two candidate genes, followed by KISS1R. Loss-offunction KISS1R mutations have been found in only 2% of patients with nCHH (8) . Most of these mutations are missense mutations (Supplemental Table 1 ) that impeded ligand-induced activation of the mutated receptor or its expression at the cell surface (4, 6, 8, 10, 11, 15) . The functional analyses of L318P-KISS1R in our study showed an absence of IP accumulation under kisspeptin stimulation and undetectable receptor expression at the cell membrane. This missense mutation within the seventh transmembrane domain therefore produces receptor misfolding, which can disturb its intracellular trafficking or can induce its premature degradation. In the patient reported here, gonadotropin levels were normal and therefore inappropriate for the estradiol levels. Normal levels of gonadotropins have been reported in very few KISS1R-mutated adult patients (3, 7, 8, 12) . Levels of AMH and inhibin B were undetectable in the proband, whereas the GnRH test produced a highnormal gonadotropin response. This dissociated biological pattern is relatively uncommon in CHH and indicates partial gonadotropin deficiency. The normal basal LH level indicates that gonadotropes receive basal GnRH inputs. This is surprising in a patient in whom KISS1R function is supposed to be completely inactivated in vivo. Indeed, kisspeptins are very potent GnRH secretagogues in almost all species. For instance, very low kisspeptin doses administered subcutaneously cause large GnRH-induced increases in LH and FSH blood levels in humans (20) , and GnRH pulses are controlled by kisspeptin release (31) . The dissociation between the complete inactivation of KISS1R in vitro and the partial gonadotropic deficiency suggests that a substantial proportion of the basal GnRH release may be kisspeptin independent, at least in humans.
The functional impact of KISS1R loss-of-function mutations is evaluated based on the kisspeptin-induced IP increase in heterologous cells, such as HEK293 or COS7 cells, expressing high levels of KISS1R. This strategy tests intrinsic KISS1R function but not the activity of the mutated receptor in the in vivo physiological cellular context. The apparently preserved basal GnRH release in our patient with a complete KISS1R inactivation in HEK293 cells may be ascribable to cellular KISS1R trafficking differences between heterologous kidney cells and native neuronal cells.
In few studies, pulsatile GnRH or hCG/rhFSH treatment restored fertility in male and female patients with KISS1R mutations (6, 9, 12) . The case reported here confirms that pulsatile GnRH treatment can induce ovulation in patients with KISS1R-inactivating mutations (12) . Since the discovery that kisspeptin contributes to regulate GnRH release, several experimental studies have demonstrated that kisspeptin signaling is mandatory for the occurrence of an LH surge in rodents (2, 25) . On the night of proestrus, the LH surge occurs in rodents when positive estradiol feedback to preoptic area (POA) neurons, including kisspeptin neurons, is added to a background circadian neural signal (32) . In nonhuman primates, the link between kisspeptin and the LH ovulatory surge is less clear. Kisspeptin participates in GnRH pulse generation (33) , KISS1 expression increases in the caudal arcuate nucleus at the end of the follicular phase (34) , and POA KISS1 expression is controlled by estradiol in female monkeys (35, 36) . However, older studies showed that the POA was not necessary for LH surge generation in nonhuman primates (37) , which questions the link between the hormonal control of KISS1 expression in the POA and the LH surge. In women, the link between kisspeptin and the induction of the LH surge is even less clear. The positive estradiol feedback on the gonadotropic axis may occur only at the pituitary level (38) . No evidence of a GnRH surge triggering the LH surge exists, and GnRH release may even decline concomitantly with the LH surge (39) . In GnRH-deficient women with Kallmann syndrome, subcutaneous GnRH pulses at a fixed frequency induce an LH surge with ovulation (40) . Thus, neither an increase in GnRH pulse frequency nor a GnRH surge is needed to induce an LH surge in women. Our findings suggest that kisspeptin signaling is not required to induce an LH surge in women receiving exogenous GnRH pulses and constitute further evidence that the LH surge in women treated with a GnRH pump is mainly mediated by positive estradiol feedback on the pituitary.
Patients with KISS1R mutations exhibit variable responses to pulsatile GnRH therapy, ranging from no response to normal plasma LH and FSH level increases (6, 9, 12) . This variability has been reported even during sex steroid treatment (12) . In keeping with these clinical data, GnRH-induced LH pulses persisted during the LH surge in our patient. Similar findings have been obtained at the midcycle in normal women (39) . This pattern of LH surge combined with persistent GnRH-induced LH pulses may result from the mobilization of two different LH vesicle pools within gonadotropes. One pool (reserve), located at a distance from the cell membrane, develops under the combined effects on the pituitary of positive estradiol feedback and GnRH stimulation. The other pool (ready-to-be-released), located close to the cell membrane, releases LH at each GnRH pulse. Under this dual-pool hypothesis, our data indicate that KISS1R signaling pathway does not significantly contribute to the development or release of reserve LH vesicles in response to pulsatile GnRH treatment.
In human female or male patients with gonadotropin deficiency, low inhibin B and AMH levels correlate with FSH levels (41) (42) (43) . Low AMH is a biomarker of inadequate gonad stimulation by FSH. Normal LH and FSH levels were combined in our patient with undetectable inhibin B and low AMH levels. These results can be related to the kisspeptin pathway defect impairing LH and FSH bioactivity but could also be related to an ovarian abnormality manifesting as an impaired ovarian response to FSH in the context of an impaired kisspeptin signaling pathway. Kiss1 and Kiss1r expression was demonstrated in rat ovary, and kisspeptin immunoreactivity in the ovaries was found in other mammals, including humans (44) . In a recent study in rats, Kiss1r haplo-insufficiency caused premature ovarian failure despite preserved gonadotropin secretion (45) . Thus, impaired ovarian function may participate in the infertility seen in women with KISS1R mutations.
The expression of KISS1R in human endometrial cells is consistent with a recent report that kisspeptin promotes endometrial gland development and function in mice (46) . In addition, circulating kisspeptin levels correlated with fertility rates in women undergoing fertility treatment by intracytoplasmic sperm injection (47, 48) . Women with unexplained infertility had lower circulating kisspeptin levels compared with patients with infertility due to known factors (48) . Furthermore, fertilized oocytes and endometrial thickness correlated with kisspeptin levels (48) . In female patients with KISS1R mutations, a poor response to pulsatile GnRH treatment may be related to defective KISS1R signaling in the endometrium and ovaries.
In summary, we report a homozygous KISS1R mutation in a Senegalese woman with nCHH. This mutation impedes KISS1R expression at the surface of HEK293 cells and is associated with a complete functional inactivation. However, the gonadotropin deficiency was only partial, indicating incomplete KISS1R signaling impairment in vivo or a kisspeptin-independent mechanism regulating basal GnRH release. The kisspeptin signaling pathway is not involved in controlling the LH surge during exogenous pulsatile GnRH treatment. The poor endometrial response to GnRH treatment associated with the expression of KISS1R in epithelial cells of the endometrium suggest a role for kisspeptin receptor signaling in endometrial maturation. In-vivo investigations are needed to further characterize these additional physiological kisspeptin receptor functions in humans.
